| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95d7c0eaa68ee59f9c9986e7fb6d0b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f28306adab6953d083eb8b65acbbad0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1005fb53db203969fab84a916931d38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7171c61e9aa2d6f03cc0a72978bc3b2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a5e8dccd18c0d44af99ec42842e327d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2014-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82c91bf958ff2be8cdda5d4b80b4ce59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36e39196a1e8d49011e330e94395b101
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed7701fba8cfc01cb46decd0561e8e0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ab8b7f64656d44bc3baa3fdfe206bf5 |
| publicationDate |
2015-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015086727-A2 |
| titleOfInvention |
New prognostic method for patients suffering of a cancer |
| abstract |
The present invention relates to an in vitro method for classifying a patient suffering from cancer comprising the steps consisting of i) determining the expression level of PLCγl in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing the stage of the patient according to the expression level of PLCγl. The invention also relates to an agonist of CD47 receptor for use in the treatment of patient suffering of a cancer with a high expression level of PLCγ. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017143894-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106661593-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11180552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019005757-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017194627-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11759496-B2 |
| priorityDate |
2013-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |